{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:30:58Z","timestamp":1787020258986,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15264-9","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:37:16Z","timestamp":1764333436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6804-9746","authenticated-orcid":false,"given":"Natalia","family":"Fern\u00e1ndez-D\u00edaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Mateos-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pertejo-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Diego","family":"Cacho-Lav\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Juan-Fita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Chirivella-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Arruti-Ibarbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"Fern\u00e1ndez-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Fern\u00e1ndez-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"M\u00e9ndez-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"L\u00e1zaro-Quintela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurea","family":"Molina-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"Del Pozo-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatz","family":"Etxaniz-Ulazia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Margarita","family":"Garc\u00eda-Acu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoel Z.","family":"Betancor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Azueta-Etxebarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Calatrava-Fons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Lombard\u00eda-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Alarc\u00f3n-Molero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leire","family":"Etxegarai-Ganboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Ant\u00f3n-Cameselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Bello-Giz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Manuel","family":"Neira-De Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Cabaleiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Gonz\u00e1lez-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Ortiz-Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Sacrist\u00e1n-Lista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Garc\u00eda-Rub\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carrato-Mo\u00f1ino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Agu\u00edn-Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Le\u00f3n-Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Pinto-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"L\u00f3pez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urbano","family":"Anido-Herranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0755-4295","authenticated-orcid":false,"given":"Juan","family":"Ruiz-Ba\u00f1obre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"15264_CR1","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354\u201366.","journal-title":"N Engl J Med"},{"key":"15264_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, et al. Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:692\u2013706.","journal-title":"Ann Oncol"},{"key":"15264_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/367354","volume":"2015","author":"R Raman","year":"2015","unstructured":"Raman R, Vaena D. Immunotherapy in metastatic renal cell carcinoma: a comprehensive review. Biomed Res Int. 2015;2015:367354.","journal-title":"Biomed Res Int"},{"key":"15264_CR4","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"15264_CR5","unstructured":"US Food and Drug Administration. FDA expands use of immunotherapeutic to kidney cancer. 2015. Available from: http:\/\/blog.aacr.org\/fda-approval-nivolumab-kidney-cancer\/. Cited 2024 Nov 20."},{"key":"15264_CR6","unstructured":"European Medicines Agency. Assessment report. Opdivo\u00ae (nivolumab). 2016. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Assessment_Report_-_Variation\/human\/003985\/WC500205974.pdf. Cited 2024 Nov 20."},{"key":"15264_CR7","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e213","volume":"33","author":"HS Kim","year":"2018","unstructured":"Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33:e213.","journal-title":"J Korean Med Sci"},{"key":"15264_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.euf.2021.11.006","volume":"8","author":"MO Grimm","year":"2022","unstructured":"Grimm MO, et al. Real-world data on the use of nivolumab monotherapy in the treatment of advanced renal cell carcinoma after prior therapy: interim results from the noninterventional NORA study. Eur Urol Focus. 2022;8:1289\u201399.","journal-title":"Eur Urol Focus"},{"key":"15264_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bju.14461","volume":"123","author":"U De Giorgi","year":"2019","unstructured":"De Giorgi U, et al. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. BJU Int. 2019;123:98\u2013105.","journal-title":"BJU Int"},{"key":"15264_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.eururo.2021.05.020","volume":"80","author":"J Courcier","year":"2021","unstructured":"Courcier J, et al. Primary renal tumour response in patients treated with nivolumab for metastatic renal cell carcinoma: results from the GETUG-AFU 26 NIVOREN trial. Eur Urol. 2021;80:325\u20139.","journal-title":"Eur Urol"},{"key":"15264_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09694-y","volume":"22","author":"T Waddell","year":"2022","unstructured":"Waddell T, et al. Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study. BMC Cancer. 2022;22:617.","journal-title":"BMC Cancer"},{"key":"15264_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.617","volume":"38","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ. Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2020;38:617.","journal-title":"J Clin Oncol"},{"key":"15264_CR13","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.eururo.2017.02.010","volume":"72","author":"B Escudier","year":"2017","unstructured":"Escudier B. Checkmate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017;72:962\u201371.","journal-title":"Eur Urol"},{"key":"15264_CR14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4274\/jus.2006","volume":"5","author":"\u0130 Akarken","year":"2018","unstructured":"Akarken \u0130, Dere Y, Tarhan H, Delikta\u015f H, \u015eahin H. Gender-related differences in surgically treated patients with renal cell carcinoma. J Urol Surg. 2018;5:170\u20133.","journal-title":"J Urol Surg"},{"key":"15264_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1046\/j.1464-410X.2002.02798.x","volume":"90","author":"T Onishi","year":"2002","unstructured":"Onishi T, Oishi Y, Goto H, Yanada S, Abe K. Gender as a prognostic factor in patients with renal cell carcinoma. BJU Int. 2002;90:32\u20136.","journal-title":"BJU Int"},{"key":"15264_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03601-6","volume":"20","author":"SE Rebuzzi","year":"2022","unstructured":"Rebuzzi SE, et al. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. J Transl Med. 2022;20:435.","journal-title":"J Transl Med"},{"key":"15264_CR17","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1200\/JCO.18.02218","volume":"37","author":"R Flippot","year":"2019","unstructured":"Flippot R, et al. Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. J Clin Oncol. 2019;37:2008\u201316.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15264-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15264-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15264-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:37:17Z","timestamp":1764333437000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15264-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15264"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15264-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee for Research with medicinal products of Galicia (2020\/248), the Ethics Committee for Research with medicinal products of Euskadi (EPA2020065), the Ethics Committee for Research with medicinal products of Cantabria, the Ethics Committee for Research with medicinal products of Hospital Universitario La Paz (PI-4313), the Ethics Committee for Research with medicinal products of C\u00f3rdoba (1584-N-20), and the Ethics Committee for Research at Hospital Universitario Elche-Vinalop\u00f3. The study was conducted in accordance with the guidelines of Good Clinical Practice and the Declaration of Helsinki. All living patients provided written informed consent before enrollment. Informed consent was waived for deceased patients before study initiation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Natalia Fern\u00e1ndez-D\u00edaz \u2014 Travel, accommodations, and expenses: GlaxoSmithKline, Lilly, Roche, Pierre Fabre, Novartis, and Sanofi; Mar\u00eda Mateos-Gonz\u00e1lez \u2014 Travel, accommodations, and expenses: AstraZeneca, Bristol-Myers Squibb, MSD, Roche, Sanofi, and Takeda; Educational activities: AstraZeneca, Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Roche, Sanofi, and Takeda; Honoraria for consultancies: MSD; Isabel Chirivella-Gonz\u00e1lez \u2014 Travel, accommodations, and expenses: Pfizer, Bristol-Myers Squibb, MSD, and Ipsen; Honoraria for consultancies: Pfizer, Bristol-Myers Squibb, Ipsen, MSD, and Roche; Honoraria as speaker: Pfizer, Bristol-Myers Squibb, and Ipsen; Ovidio Fern\u00e1ndez-Calvo \u2014 Travel, accommodations, and expenses: Bristol-Myers Squibb, Ipsen, and Astellas; Honoraria for consultancies: Astellas, Pfizer, Bristol-Myers Squibb, Ipsen, Merck, and Eisai; Honoraria as speaker: Novartis, Bristol-Myers Squibb, Ipsen, Roche, Astellas, and Bayer; Mart\u00edn L\u00e1zaro-Quintela \u2014 Honoraria as speaker: MSD, Bristol-Myers Squibb, and Ipsen; Advisory board: Ipsen, Astellas; Aurea Molina-D\u00edaz \u2014 Travel, accommodations, and expenses: Eisai, Gr\u00fcnenthal Pharma, Kyowa Kirin, PharmaMar, Merck, Bristol-Myers Squibb, Roche, and Ipsen; Honoraria for educational activities: Pfizer, Bristol-Myers Squibb, MSD, Eisai, Kyowa Kirin, Merck, PharmaMar, AstraZeneca, Lilly, Sanofi, Takeda, Astellas, Roche, and Pierre Fabre; Advisory board: Bayer, Eisai, Pierre Fabre, PharmaMar, Pfizer, and Merck; Santiago Agu\u00edn-Losada \u2014 Travel, accommodations, and expenses: Merck, Roche, Bristol-Myers Squibb, and MSD; Honoraria for educational activities: Merck, MSD, Bristol-Myers Squibb, Sanofi, Roche, and Lilly; Honoraria for consultancies: Merck, MSD, and Bristol-Myers Squibb; Luis Le\u00f3n-Mateos \u2014 Travel, accommodations, and expenses: Bristol-Myers Squibb, Lilly, MSD, Pfizer, and Roche; Honoraria for educational activities: AstraZeneca, Boehringer Ingelheim, Novartis, Janssen, Astellas, Pfizer, and Sanofi; Honoraria for consultancies: AstraZeneca, Boehringer Ingelheim, Novartis, Janssen, Astellas, Pfizer, and Sanofi; Jorge Garc\u00eda-Gonz\u00e1lez \u2014 Travel, accommodations, and expenses: AstraZeneca, Bristol-Myers Squibb, MSD, Roche, Sanofi, and Takeda; Honoraria for educational activities: AstraZeneca, Bristol-Myers Squibb, MSD, Novartis, Pierre Fabre, Roche, Sanofi, and Takeda; Honoraria for consultancies: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Novartis, Roche, Sanofi, and Takeda; Ignacio Duran \u2014 Travel, accommodations, and expenses: Bayer, AstraZeneca, and Merck; Honoraria for educational activities: Astellas, Bristol-Myers Squibb, Merck, Ipsen, Janssen, MSD, and Genentech; Honoraria for consultancies: Astellas, MSD, Merck, Bristol-Myers Squibb, Ipsen, AstraZeneca, and Janssen; Institutional research funding: Genentech and AstraZeneca; Rafael L\u00f3pez-L\u00f3pez \u2014 Travel, accommodations, and expenses: Lilly, Novartis, Pfizer, Merck, Roche, and Bristol-Myers Squibb; Honoraria for educational activities: Lilly, Novartis, Pfizer, Merck, Roche, and Bristol-Myers Squibb; Honoraria for consultancies: PharmaMar, Bayer, and Pierre Fabre; Urbano Anido-Herranz \u2014 Travel, accommodations, and expenses: Ipsen, Bayer, Merck, Pfizer, and Sanofi; Honoraria for educational activities: Advanced Accelerator Applications (Novartis), Bayer, Ipsen, MSD, AstraZeneca, Merck, Eisai, Bristol-Myers Squibb, Kyowa Kirin, Rovi, GlaxoSmithKline, and LEO Pharma; Honoraria for consultancies: Advanced Accelerator Applications (Novartis), Ipsen, AstraZeneca, Merck, Pfizer, Astellas, and Bayer; Juan Ruiz-Ba\u00f1obre \u2014 Travel, accommodations, and expenses: Merck, Pierre Fabre, Sanofi, Seagen, and MSD; Honoraria for educational activities: Ipsen; Institutional research funding: Nouscom, Pfizer, Roche, and GlaxoSmithKline. The other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1835"}}